KLK3 and prostate cancer: In data from the ProtecT trial (n = 1291), unadjusted PSA had an AUC of 57.1%, PSA adjusted for 4 PSA-SNPs had an AUC 58.5% and the AUC when including the 23 prostate cancer risk variants was 63.3%.